Literature DB >> 1329634

Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant.

H Mentec1, J M Vallois, A Bure, A Saleh-Mghir, F Jehl, C Carbon.   

Abstract

The efficacy of tazobactam, a beta-lactamase inhibitor, in combination with piperacillin, was studied in vitro and in rabbit experimental endocarditis due to a Klebsiella pneumoniae strain (KpR) producing an extended-spectrum beta-lactamase, TEM-3, or its nonproducing variant (KpS). In vitro, piperacillin was active against KpS (MIC = 4 micrograms/ml, MBC = 8 micrograms/ml with 10(7)-CFU/ml inoculum) but not against KpR (MIC = MBC = 256 micrograms/ml). Tazobactam (1 microgram/ml) restored the activity of piperacillin against KpR (MIC = 2 micrograms/ml, MBC = 4 micrograms/ml). Gentamicin was active against both strains (MIC = 0.25 and 0.5 micrograms/ml for KpS and KpR, respectively). The piperacillin-tazobactam-gentamicin combination was synergistic in vitro. The piperacillin/tazobactam ratio in plasma and in vegetations was always lower than the 4/1 injected dose ratio. In vivo, piperacillin (300 mg/kg of body weight four times a day [QID]) was active against KpS but not against KpR. Tazobactam (75 mg/kg QID) was able to restore the in vivo effect of piperacillin (300 mg/kg QID) against KpR (-3.0 log10 CFU/g of vegetation versus that of controls). Gentamicin (4 mg/kg twice a day [BID]) was active against both strains. Compared with controls, the combination of gentamicin plus piperacillin against KpS (-5.6 log10 CFU/g of vegetation), and the gentamicin-piperacillin-tazobactam combination against KpR (-4.4 log10 CFU/g of vegetation) achieved the greatest decrease in bacterial counts in vegetations and were the only regimens that significantly increased the proportion of sterile vegetations. It is concluded that (i) tazobactam was able to restore the effect of piperacillin against a TEM-3 extended-spectrum Beta-lactamase-producing strain of K. pneumoniae, both in vitro and in a severe experimental infection with high inoculum, when used in a 4/1 piperacillin/tazobactam dose ratio; (ii) gentamicin alone was effective because of the high peak/MBC ratio in plasma; (iii) piperacillin-tazobactam-gentamicin, probably because of the effect of gentamicin in reducing bacterial inoculum in vivo, as stressed by the results obtained by piperacillin-gentamicin against KpS, may be the most effective regimen against KpR.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329634      PMCID: PMC192204          DOI: 10.1128/AAC.36.9.1883

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 beta-lactamase.

Authors:  F Caron; L Gutmann; A Bure; B Pangon; J M Vallois; A Pechinot; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Extended-spectrum beta-lactamases.

Authors:  A Philippon; R Labia; G Jacoby
Journal:  Antimicrob Agents Chemother       Date:  1989-08       Impact factor: 5.191

3.  Activity of sulbactam/ampicillin in screening and discriminative animal models of infection.

Authors:  A R English; D Girard; C Cimochowski; J Faiella; J A Retsema; J E Lynch
Journal:  Rev Infect Dis       Date:  1986 Nov-Dec

Review 4.  Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated beta-lactamases markedly active against third-generation cephalosporins: epidemiologic studies.

Authors:  J Sirot; C Chanal; A Petit; D Sirot; R Labia; G Gerbaud
Journal:  Rev Infect Dis       Date:  1988 Jul-Aug

5.  Synergy of amoxycillin combined with clavulanate and YTR 830 in experimental infections in mice.

Authors:  S C Aronoff; M R Jacobs; P H Labrozzi; S Yamabe
Journal:  J Antimicrob Chemother       Date:  1986-08       Impact factor: 5.790

6.  Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanate, and sulbactam combined with ampicillin and broad-spectrum penicillins against defined beta-lactamase-producing aerobic gram-negative bacilli.

Authors:  M R Jacobs; S C Aronoff; S Johenning; D M Shlaes; S Yamabe
Journal:  Antimicrob Agents Chemother       Date:  1986-06       Impact factor: 5.191

7.  Ceftriaxone-netilmicin combination in single-daily-dose treatment of experimental Escherichia coli endocarditis.

Authors:  B Fantin; B Pangon; G Potel; J M Vallois; F Caron; A Bure; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

8.  Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae.

Authors:  C Brun-Buisson; P Legrand; A Philippon; F Montravers; M Ansquer; J Duval
Journal:  Lancet       Date:  1987-08-08       Impact factor: 79.321

9.  Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography.

Authors:  A C Cremieux; B Maziere; J M Vallois; M Ottaviani; A Azancot; H Raffoul; A Bouvet; J J Pocidalo; C Carbon
Journal:  J Infect Dis       Date:  1989-05       Impact factor: 5.226

10.  Efficacy of ampicillin plus a beta-lactamase inhibitor (CP-45,899) in experimental endocarditis due to Staphylococcus aureus.

Authors:  R G Washburn; D T Durack
Journal:  J Infect Dis       Date:  1981-09       Impact factor: 5.226

View more
  12 in total

1.  In vitro and in vivo activities of amikacin, cefepime, amikacin plus cefepime, and imipenem against an SHV-5 extended-spectrum beta-lactamase-producing Klebsiella pneumoniae strain.

Authors:  D Szabó; A Máthé; Z Filetóth; P Anderlik; L Rókusz; F Rozgonyi
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

Review 2.  Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.

Authors:  Markus Mueller; Amparo de la Peña; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

3.  Efficacies of piperacillin-tazobactam and cefepime in rats with experimental intra-abdominal abscesses due to an extended-spectrum beta-lactamase-producing strain of Klebsiella pneumoniae.

Authors:  C Thauvin-Eliopoulos; M F Tripodi; R C Moellering; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

4.  Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase.

Authors:  G Leleu; M D Kitzis; J M Vallois; L Gutmann; J M Decazes
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

Review 5.  Clinical significance of extended-spectrum beta-lactamases.

Authors:  J P Quinn
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994       Impact factor: 3.267

6.  Hospital outbreak of Klebsiella pneumoniae resistant to broad-spectrum cephalosporins and beta-lactam-beta-lactamase inhibitor combinations by hyperproduction of SHV-5 beta-lactamase.

Authors:  G L French; K P Shannon; N Simmons
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

7.  Assessment of two penicillins plus beta-lactamase inhibitors versus cefotaxime in treatment of murine Klebsiella pneumoniae infections.

Authors:  J L Fournier; F Ramisse; A C Jacolot; M Szatanik; O J Petitjean; J M Alonso; M R Scavizzi
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

Review 8.  Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment.

Authors:  Mark E Rupp; Paul D Fey
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

10.  Influence of antimicrobial therapy on kinetics of tumor necrosis factor levels in experimental endocarditis caused by Klebsiella pneumoniae.

Authors:  J Mohler; B Fantin; J L Mainardi; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.